| Project/Area Number |
19390341
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (B)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
General surgery
|
|---|
| Research Institution | Wakayama Medical University |
|---|
Principal Investigator |
YAMAUE Hiroki Wakayama Medical University, 医学部, 教授 (20191190)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
NAKAMORI Mikihito 和歌山県立医科大学, 医学部, 講師 (10322372)
IWAHASHI Makoto 和歌山県立医科大学, 医学部, 講師 (70244738)
NAKAMURA Masaki 和歌山県立医科大学, 医学部, 助教 (80364090)
|
|---|
| Project Period (FY) |
2007 – 2009
|
| Project Status |
Completed (Fiscal Year 2009)
|
| Budget Amount *help |
¥9,490,000 (Direct Cost: ¥7,300,000、Indirect Cost: ¥2,190,000)
Fiscal Year 2009: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2008: ¥2,210,000 (Direct Cost: ¥1,700,000、Indirect Cost: ¥510,000)
Fiscal Year 2007: ¥5,980,000 (Direct Cost: ¥4,600,000、Indirect Cost: ¥1,380,000)
|
|---|
| Keywords | 消化器癌 / 免疫療法 / 腫瘍抗原ペプチド / ウイルス療法 / 実験外科学 / 臨床研究 |
|---|
| Research Abstract |
Vascular endothelial growth factor receptor 2 (VEGFR2) is an essential factor in tumor angiogenesis and in the growth of pancreatic cancer. Immunotherapy using epitope peptide for VEGFR2 (VEGFR2-169) that we identified previously is expected to improve the clinical outcome. Therefore, a phase I clinical trial combining of VEGFR2-169 with gemcitabine was conducted for patients with advanced pancreatic cancer. Patients with metastatic and unresectable pancreatic cancer were eligible for the trial. In addition, we developed newly oncolytic herpes simplex viruses (HSV). This virus can produce human thrombospondin-1 (TSP-1) and induce apoptosis for human gastric cancer cell lines. In vivo experiments, our virus could suppress tumor angiogenesis.
|
